1
|
Mohamed Saini S, Bousman CA, Mancuso SG, Cropley V, Van Rheenen TE, Lenroot RK, Bruggemann J, Weickert CS, Weickert TW, Sundram S, Everall IP, Pantelis C. Genetic variation in glutamatergic genes moderates the effects of childhood adversity on brain volume and IQ in treatment-resistant schizophrenia. Schizophrenia (Heidelb) 2023; 9:59. [PMID: 37709784 PMCID: PMC10502098 DOI: 10.1038/s41537-023-00381-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Accepted: 07/20/2023] [Indexed: 09/16/2023]
Affiliation(s)
- Suriati Mohamed Saini
- Department of Psychiatry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Cheras, Kuala Lumpur, Malaysia.
- Department of Psychiatry, Hospital Canselor Tuanku Muhriz, Jalan Yaacob Latif, Cheras, Kuala Lumpur, Malaysia.
| | - Chad A Bousman
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
- Alberta Children's Hospital Research Institute, Calgary, AB, Canada
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
- Department of Medical Genetics, Psychiatry, and Physiology and Pharmacology, The University of Calgary, Calgary, AB, Canada
| | - Serafino G Mancuso
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
| | - Vanessa Cropley
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
- Centre for Mental Health, Faculty of Health, Arts and Design, Swinburne University, Melbourne, VIC, Australia
| | - Tamsyn E Van Rheenen
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
- Centre for Mental Health, Faculty of Health, Arts and Design, Swinburne University, Melbourne, VIC, Australia
| | - Rhoshel K Lenroot
- School of Psychiatry, University of New South Wales, Randwick, NSW, Australia
- Department of Psychiatry and Behavioural Science, University of New Mexico, Albuquerque, NM, USA
| | - Jason Bruggemann
- School of Psychiatry, University of New South Wales, Randwick, NSW, Australia
- Neuroscience Research Australia, Randwick, NSW, Australia
- Schizophrenia Research Institute, Sydney, NSW, Australia
| | - Cynthia S Weickert
- School of Psychiatry, University of New South Wales, Randwick, NSW, Australia
- Department of Neuroscience & Physiology, SUNY Upstate Medical University, NY, USA
- Schizophrenia Research Laboratory, Neuroscience Research Australia, NSW, Australia
| | - Thomas W Weickert
- School of Psychiatry, University of New South Wales, Randwick, NSW, Australia
- Department of Neuroscience & Physiology, SUNY Upstate Medical University, NY, USA
| | - Suresh Sundram
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
- Department of Psychiatry, School of Clinical Sciences, Monash University, Clayton, VIC, Australia
- Monash Medical Centre, Monash Health, Clayton, VIC, Australia
| | - Ian P Everall
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Christos Pantelis
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- Western Centre for Health Research & Education, Sunshine Hospital, Western Health, St Albans, VIC, 3021, Australia
| |
Collapse
|
2
|
Abstract
The transition from DSM-IV to DSM-5 relaxed diagnostic criteria for anorexia nervosa and bulimia nervosa, and recognised a third eating disorder, binge eating disorder. However, a large proportion of cases remain in the ill-defined category of 'other specified feeding and eating disorders'. We sought to investigate the utility of a proposed solution to classify this group further, subdividing based on the dominant clinical feature: binge eating/purging or restraint. Cluster analysis failed to identify clusters in a treatment-seeking sample based on symptoms of restraint, binge eating, purging and over-evaluation of shape and weight. Further investigation of this highly heterogeneous group is required.
Collapse
Affiliation(s)
- Zoe M Jenkins
- Department of Mental Health, St. Vincent's Hospital, Melbourne, Australia, and Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| | - Serafino G Mancuso
- Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| | - Andrea Phillipou
- Department of Mental Health, St. Vincent's Hospital, Melbourne, Australia, Department of Psychiatry, The University of Melbourne, Melbourne, Australia, and Centre for Mental Health, Swinburne University of Technology, Melbourne, Australia
| | - David J Castle
- Department of Mental Health, St. Vincent's Hospital, Melbourne, Australia, and Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| |
Collapse
|
3
|
Bousman CA, Luza S, Mancuso SG, Kang D, Opazo CM, Mostaid MS, Cropley V, McGorry P, Shannon Weickert C, Pantelis C, Bush AI, Everall IP. Elevated ubiquitinated proteins in brain and blood of individuals with schizophrenia. Sci Rep 2019; 9:2307. [PMID: 30783160 PMCID: PMC6381171 DOI: 10.1038/s41598-019-38490-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Accepted: 12/31/2018] [Indexed: 12/19/2022] Open
Abstract
Dysregulation of the ubiquitin proteasome system (UPS) has been linked to schizophrenia but it is not clear if this dysregulation is detectable in both brain and blood. We examined free mono-ubiquitin, ubiquitinated proteins, catalytic ubiquitination, and proteasome activities in frozen postmortem OFC tissue from 76 (38 schizophrenia, 38 control) matched individuals, as well as erythrocytes from 181 living participants, who comprised 30 individuals with recent onset schizophrenia (mean illness duration = 1 year), 63 individuals with 'treatment-resistant' schizophrenia (mean illness duration = 17 years), and 88 age-matched participants without major psychiatric illness. Ubiquitinated protein levels were elevated in postmortem OFC in schizophrenia compared to controls (p = <0.001, AUC = 74.2%). Similarly, individuals with 'treatment-resistant' schizophrenia had higher levels of ubiquitinated proteins in erythrocytes compared to those with recent onset schizophrenia (p < 0.001, AUC = 65.5%) and controls (p < 0.001, AUC = 69.4%). The results could not be better explained by changes in proteasome activity, demographic, medication, or tissue factors. Our results suggest that ubiquitinated protein formation may be abnormal in both the brain and erythrocytes of those with schizophrenia, particularly in the later stages or specific sub-groups of the illness. A derangement in protein ubiquitination may be linked to pathogenesis or neurotoxicity in schizophrenia, and its manifestation in the blood may have prognostic utility.
Collapse
Affiliation(s)
- Chad A Bousman
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia
- The Cooperative Research Centre (CRC) for Mental Health, Victoria, Australia
- Departments of Medical Genetics, Psychiatry, Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada
- Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada
- Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
| | - Sandra Luza
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia
- Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Serafino G Mancuso
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia
| | - Dali Kang
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia
- Guangdong Food and Drug Vocational College, Guangzhou, China
| | - Carlos M Opazo
- Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Md Shaki Mostaid
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia
- The Cooperative Research Centre (CRC) for Mental Health, Victoria, Australia
| | - Vanessa Cropley
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia
| | - Patrick McGorry
- Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia
- NorthWestern Mental Health, Melbourne, Victoria, Australia
| | - Cynthia Shannon Weickert
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Baker Street, Sydney, Australia
- School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Christos Pantelis
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia
- The Cooperative Research Centre (CRC) for Mental Health, Victoria, Australia
- Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- NorthWestern Mental Health, Melbourne, Victoria, Australia
- Centre for Neural Engineering, The University of Melbourne, Carlton, VIC, Australia
| | - Ashley I Bush
- The Cooperative Research Centre (CRC) for Mental Health, Victoria, Australia.
- Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.
| | - Ian P Everall
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia.
- The Cooperative Research Centre (CRC) for Mental Health, Victoria, Australia.
- Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.
- Centre for Neural Engineering, The University of Melbourne, Carlton, VIC, Australia.
- Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
| |
Collapse
|
4
|
Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics 2019; 20:37-47. [DOI: 10.2217/pgs-2018-0142] [Citation(s) in RCA: 93] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Aim: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD). Patients & methods: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria. Results & conclusion: A total of 1737 eligible subjects from five RCTs were examined. Individuals receiving pharmacogenetic-guided DST therapy (n = 887) were 1.71 (95% CI: 1.17–2.48; p = 0.005) times more likely to achieve symptom remission relative to individuals who received treatment as usual (n = 850). Pharmacogenetic-guided DSTs might improve symptom remission among those with MDD.
Collapse
Affiliation(s)
- Chad A Bousman
- Departments of Medical Genetics, Psychiatry, & Physiology & Pharmacology, University of Calgary, Calgary, Alberta T2N 4N1, Canada
- Alberta Children's Hospital Research Institute, Calgary, Alberta T2N 1N4, Canada
- Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Katarina Arandjelovic
- IMPACT SRC, School of Medicine, Deakin University, Geelong, Victoria, 3220, Australia
| | - Serafino G Mancuso
- Department of Psychiatry, University of Melbourne, Melbourne, Victoria, 3220, Australia
| | - Harris A Eyre
- IMPACT SRC, School of Medicine, Deakin University, Geelong, Victoria, 3220, Australia
- Department of Psychiatry, University of Melbourne, Melbourne, Victoria, 3220, Australia
- Innovation Institute, Texas Medical Center, Houston, TX 77030, USA
- CNSDose LLC, Westlake Village, CA 91359, USA
| | - Boadie W Dunlop
- Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
| |
Collapse
|
5
|
Hoffmann C, Van Rheenen TE, Mancuso SG, Zalesky A, Bruggemann J, Lenroot RK, Sundram S, Weickert CS, Weickert TW, Pantelis C, Cropley V, Bousman CA. Exploring the moderating effects of dopaminergic polymorphisms and childhood adversity on brain morphology in schizophrenia-spectrum disorders. Psychiatry Res Neuroimaging 2018; 281:61-68. [PMID: 30253269 DOI: 10.1016/j.pscychresns.2018.09.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 09/11/2018] [Accepted: 09/11/2018] [Indexed: 12/18/2022]
Abstract
Genetic and environmental etiologies may contribute to schizophrenia and its associated neurobiological profile. We examined the interaction between dopaminergic polymorphisms, childhood adversity and diagnosis (schizophrenia/schizoaffective disorder) on dopamine-related brain structures. Childhood adversity histories and structural MRI data were obtained from 249 (153 schizophrenia/schizoaffective, 96 controls) participants registered in the Australian Schizophrenia Research Bank. Polymorphisms in DRD2 and COMT were genotyped and a dopaminergic risk allelic load (RAL) was calculated. Regression analysis was used to test the main and interaction effects of RAL, childhood adversity and diagnosis on volumes of dopamine-related brain structures (caudate, putamen, nucleus accumbens, dorsolateral prefrontal cortex and hippocampus). A schizophrenia/schizoaffective diagnosis showed significant main effects on bilateral hippocampus, left dorsolateral prefrontal cortex and bilateral putamen volumes. RAL showed a significant main effect on left putamen volumes. Furthermore, across the whole sample, a significant two-way interaction between dopaminergic RAL and childhood adversity was found for left putamen volumes. No brain structure volumes were predicted by a three-way interaction that included diagnosis. Our finding suggests the left putamen may be particularly sensitive to dopaminergic gene-environment interactions regardless of diagnosis. However, larger studies are needed to assess whether these interactions are more or less pronounced in those with schizophrenia/schizoaffective disorders.
Collapse
Affiliation(s)
- Cassandra Hoffmann
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia
| | - Tamsyn E Van Rheenen
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne University, Melbourne, Australia
| | - Serafino G Mancuso
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia
| | - Andrew Zalesky
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia
| | - Jason Bruggemann
- School of Psychiatry, University of New South Wales, Australia; Neuroscience Research Australia, New South Wales, Australia; Schizophrenia Research Institute, Sydney, New South Wales, Australia
| | - Rhoshel K Lenroot
- School of Psychiatry, University of New South Wales, Australia; Neuroscience Research Australia, New South Wales, Australia; Schizophrenia Research Institute, Sydney, New South Wales, Australia; Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, USA
| | - Suresh Sundram
- Florey Institute of Neuroscience and Mental Health, Australia; Department of Psychiatry, School of Clinical Sciences, Monash University, Clayton, Australia; Mental Health Program, Monash Health, Clayton, Victoria, Australia
| | - Cynthia Shannon Weickert
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; School of Psychiatry, University of New South Wales, Australia; Neuroscience Research Australia, New South Wales, Australia; Schizophrenia Research Institute, Sydney, New South Wales, Australia; Department of Neuroscience & Physiology, Upstate Medical University, Syracuse, New York, USA
| | - Thomas W Weickert
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; School of Psychiatry, University of New South Wales, Australia; Neuroscience Research Australia, New South Wales, Australia; Schizophrenia Research Institute, Sydney, New South Wales, Australia
| | - Christos Pantelis
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; Florey Institute of Neuroscience and Mental Health, Australia; Department of Electrical and Electronic Engineering, University of Melbourne, Victoria, Australia
| | - Vanessa Cropley
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne University, Melbourne, Australia
| | - Chad A Bousman
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; Departments of Medical Genetics, Psychiatry, and Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada.
| |
Collapse
|
6
|
Hocking DC, Mancuso SG, Sundram S. Development and validation of a mental health screening tool for asylum-seekers and refugees: the STAR-MH. BMC Psychiatry 2018; 18:69. [PMID: 29548315 PMCID: PMC5857116 DOI: 10.1186/s12888-018-1660-8] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Accepted: 03/12/2018] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND There is no screening tool for major depressive disorder (MDD) or post-traumatic stress disorder (PTSD) in asylum-seekers or refugees (ASR) that can be readily administered by non-mental health workers. Hence, we aimed to develop a brief, sensitive and rapidly administrable tool for non-mental health workers to screen for MDD and PTSD in ASR. METHODS The screening tool was developed from an extant dataset (n = 121) of multiply screened ASR and tested prospectively (N = 192) against the M.I.N.I. (Mini International Neuropsychiatric Interview) structured psychiatric interview. Rasch, Differential Item Functioning and ROC analyses evaluated the psychometric properties and tool utility. RESULTS A 9-item tool with a median administration time of six minutes was generated, comprising two 'immediate screen-in' items, and a 7-item scale. The prevalence of PTSD &/or MDD using the M.I.N.I. was 32%, whilst 99% of other diagnosed mental disorders were comorbid with one or both of these. Using a cut-score of ≥2, the tool provided a sensitivity of 0.93, specificity of 0.75 and predictive accuracy of 80.7%. CONCLUSIONS A brief sensitive screening tool with robust psychometric properties that was easy to administer at the agency of first presentation was developed to facilitate mental health referrals for asylum-seekers and new refugees.
Collapse
Affiliation(s)
- Debbie C. Hocking
- Cabrini Institute, 154 Wattletree Road, Malvern, VIC 3144 Australia ,0000 0004 0606 5526grid.418025.aFlorey Institute of Neuroscience and Mental Health, 30 Royal Parade (Cnr Genetics Lane), Parkville, VIC 3052 Australia ,0000 0004 1936 7857grid.1002.3Department of Psychiatry, School of Clinical Sciences, Monash University, Clayton, VIC 3168 Australia
| | - Serafino G. Mancuso
- 0000 0001 2179 088Xgrid.1008.9Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC 3010 Australia
| | - Suresh Sundram
- 0000 0004 0606 5526grid.418025.aFlorey Institute of Neuroscience and Mental Health, 30 Royal Parade (Cnr Genetics Lane), Parkville, VIC 3052 Australia ,0000 0001 2179 088Xgrid.1008.9Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC 3010 Australia ,0000 0004 1936 7857grid.1002.3Department of Psychiatry, School of Clinical Sciences, Monash University, Clayton, VIC 3168 Australia ,0000 0004 0390 1496grid.416060.5Adult Psychiatry, Monash Medical Centre, Clayton, VIC 3168 Australia
| |
Collapse
|
7
|
Grant M, Ugalde A, Mancuso SG, Vafiadis P, Philip J. Morphine use in cancer care: A survey of attitudes and perceptions in general practice patients. Aust Fam Physician 2017; 46:775-780. [PMID: 29036780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
BACKGROUND Morphine is widely prescribed for patients with cancer, although a number of attitudes have been cited as barriers to its use, including fear, addiction and associations with death. The aim of this study was to explore the nature of these beliefs, and assess the extent to which these attitudes exist in a general practice patient population that may require morphine in the future. METHODS A 30-item survey was distributed through general practices in Victoria, Australia. RESULTS Of the 379 questionnaires distributed, 290 were collected (76.5%). Participants were predominantly neutral on questions regarding the effect of morphine on the duration of life. Morphine was seen to be prescribed responsibly (73.5%), even while most perceived its potential for addiction (69.7%). Participants with experience of morphine use had more negative perceptions regarding its efficacy. DISCUSSION Conversations regarding morphine use should include a discussion about the beliefs and experiences of the individual, many of which may reinforce the utility of morphine.
Collapse
|
8
|
Saini SM, Mancuso SG, Mostaid MS, Liu C, Pantelis C, Everall IP, Bousman CA. Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk. Transl Psychiatry 2017; 7:e1196. [PMID: 28786982 PMCID: PMC5611739 DOI: 10.1038/tp.2017.172] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2017] [Accepted: 06/20/2017] [Indexed: 12/29/2022] Open
Abstract
Genome-wide association study (GWAS) evidence has identified the metabotropic glutamate receptor 3 (GRM3) gene as a potential harbor for schizophrenia risk variants. However, previous meta-analyses have refuted the association between GRM3 single-nucleotide polymorphisms (SNPs) and schizophrenia risk. To reconcile these conflicting findings, we conducted the largest and most comprehensive meta-analysis of 14 SNPs in GRM3 from a total of 11 318 schizophrenia cases, 13 820 controls and 486 parent-proband trios. We found significant associations for three SNPs (rs2237562: odds ratio (OR)=1.06, 95% confidence interval (CI)=1.02-1.11, P=0.017; rs13242038: OR=0.90, 95% CI=0.85-0.96, P=0.016 and rs917071: OR=0.94, 95% CI=0.91-0.97, P=0.003). Two of these SNPs (rs2237562, rs917071) were in strong-to-moderate linkage disequilibrium with the top GRM3 GWAS significant SNP (rs12704290) reported by the Schizophrenia Working Group of the Psychiatric Genomics Consortium. We also found evidence for population stratification related to rs2237562 in that the 'risk' allele was dependent on the population under study. Our findings support the GWAS-implicated link between GRM3 genetic variation and schizophrenia risk as well as the notion that alleles conferring this risk may be population specific.
Collapse
Affiliation(s)
- S M Saini
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
- Department of Psychiatry, UKM Medical Center, Jalan Yaacob Latif, Cheras, Kuala Lumpur, Malaysia
| | - S G Mancuso
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
| | - Md S Mostaid
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
| | - C Liu
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
| | - C Pantelis
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- Centre for Neural Engineering, The University of Melbourne, Carlton, VIC, Australia
- North Western Mental Health, Melbourne Health, Parkville, VIC, Australia
| | - I P Everall
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- Centre for Neural Engineering, The University of Melbourne, Carlton, VIC, Australia
- North Western Mental Health, Melbourne Health, Parkville, VIC, Australia
| | - C A Bousman
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- Department of General Practice, The University of Melbourne, Parkville, VIC, Australia
| |
Collapse
|
9
|
Mostaid MS, Mancuso SG, Liu C, Sundram S, Pantelis C, Everall IP, Bousman CA. Meta-analysis reveals associations between genetic variation in the 5' and 3' regions of Neuregulin-1 and schizophrenia. Transl Psychiatry 2017; 7:e1004. [PMID: 28094814 PMCID: PMC5545738 DOI: 10.1038/tp.2016.279] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2016] [Accepted: 11/27/2016] [Indexed: 01/07/2023] Open
Abstract
Genetic, post-mortem and neuroimaging studies repeatedly implicate neuregulin-1 (NRG1) as a critical component in the pathophysiology of schizophrenia. Although a number of risk haplotypes along with several genetic polymorphisms in the 5' and 3' regions of NRG1 have been linked with schizophrenia, results have been mixed. To reconcile these conflicting findings, we conducted a meta-analysis examining 22 polymorphisms and two haplotypes in NRG1 among 16 720 cases, 20 449 controls and 2157 family trios. We found significant associations for three polymorphisms (rs62510682, rs35753505 and 478B14-848) at the 5'-end and two (rs2954041 and rs10503929) near the 3'-end of NRG1. Population stratification effects were found for the rs35753505 and 478B14-848(4) polymorphisms. There was evidence of heterogeneity for all significant markers and the findings were robust to publication bias. No significant haplotype associations were found. Our results suggest genetic variation at the 5' and 3' ends of NRG1 are associated with schizophrenia and provide renewed justification for further investigation of NRG1's role in the pathophysiology of schizophrenia.
Collapse
Affiliation(s)
- M S Mostaid
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Carlton South, VIC, Australia
| | - S G Mancuso
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Carlton South, VIC, Australia
| | - C Liu
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Carlton South, VIC, Australia
| | - S Sundram
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- NorthWestern Mental Health, Melbourne Health, Parkville, VIC, Australia
- Department of Psychiatry, School of Clinical Sciences, Monash University and Monash Health, Clayton, VIC, Australia
| | - C Pantelis
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Carlton South, VIC, Australia
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- NorthWestern Mental Health, Melbourne Health, Parkville, VIC, Australia
- Centre for Neural Engineering (CfNE), Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia
| | - I P Everall
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Carlton South, VIC, Australia
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- NorthWestern Mental Health, Melbourne Health, Parkville, VIC, Australia
- Centre for Neural Engineering (CfNE), Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia
| | - C A Bousman
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Carlton South, VIC, Australia
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- Department of General Practice, The University of Melbourne, Parkville, VIC, Australia
- Swinburne University of Technology, Centre for Human Psychopharmacology, Hawthorn, VIC, Australia
| |
Collapse
|
10
|
Mancuso SG. Body image inflexibility mediates the relationship between body image evaluation and maladaptive body image coping strategies. Body Image 2016; 16:28-31. [PMID: 26595857 DOI: 10.1016/j.bodyim.2015.10.003] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2015] [Revised: 10/16/2015] [Accepted: 10/19/2015] [Indexed: 11/17/2022]
Abstract
Body image inflexibility, the unwillingness to experience negative appearance-related thoughts and emotions, is associated with negative body image and eating disorder symptoms. The present study investigated whether body image inflexibility mediated the relationship between body image evaluation and maladaptive body image coping strategies (appearance-fixing and experiential avoidance) in a college and community sample comprising 156 females aged 18-51 years (M=22.76, SD=6.96). Controlling for recruitment source (college vs. community), body image inflexibility fully mediated the relationship between body image evaluation and maladaptive body image coping strategies. Results indicated that an unwillingness to experience negative appearance-related thoughts and emotions is likely responsible for negative body image evaluation's relationship to appearance-fixing behaviours and experiential avoidance. Findings support extant evidence that interventions that explicitly target body image inflexibility, such as Acceptance and Commitment Therapy, may have utility in treating body dissatisfaction in nonclinical populations.
Collapse
Affiliation(s)
- Serafino G Mancuso
- Department of Psychiatry, The University of Melbourne, Parkville, Australia; Department of Medicine, The University of Melbourne at St Vincent's Hospital, Fitzroy, Australia.
| |
Collapse
|
11
|
Stolk Y, Sevar K, Tran N, Mancuso SG, Chopra P, Castle D. A comparative study of the economic and social functioning of Vietnamese-Australians with low English proficiency living with psychotic illness. Int J Soc Psychiatry 2015; 61:319-29. [PMID: 25080442 DOI: 10.1177/0020764014543710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Because national surveys of people living with psychotic disorders tend to exclude people with low English proficiency (LEP), little is known of their economic and social functioning. Culturally influenced explanatory models may result in delayed presentation and poorer functioning. AIMS The study aimed to compare the functioning of LEP Vietnamese-Australian and Australian-born patients with psychosis and to investigate the Vietnamese-Australians' pathways to care. METHOD In all, 19 LEP Vietnamese-Australians, previously excluded from the Australian Survey of High Impact Psychosis (SHIP), were matched with 15 Australian-born controls, and interviewed by a Vietnamese bilingual mental health professional using the SHIP Interview Schedule. RESULTS The Vietnamese-Australian patients were significantly more likely to live with family, rate spirituality as important and participate in community rehabilitation programs. Their work, social and independent functioning, was better than the controls. The groups did not differ in mental health services received and satisfaction with services. Although half of Vietnamese-Australians attributed mental illness to supernatural, among other causes, none had consulted traditional healers. CONCLUSIONS Despite LEP, Vietnamese-Australians with psychosis showed comparable or better functioning than Australian-born patients. Further investigation is recommended into LEP patients' clinical and social recovery and the role of language communities' support networks.
Collapse
Affiliation(s)
- Yvonne Stolk
- Transcultural Psychology Consultant, Melbourne, VIC, Australia
| | - Katherine Sevar
- St Vincent's Mental Health, Fitzroy, VIC, Australia Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| | - Nga Tran
- St Vincent's Mental Health, Fitzroy, VIC, Australia Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| | - Serafino G Mancuso
- St Vincent's Mental Health, Fitzroy, VIC, Australia Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| | - Prem Chopra
- St Vincent's Mental Health, Fitzroy, VIC, Australia
| | - David Castle
- St Vincent's Mental Health, Fitzroy, VIC, Australia Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia Department of Psychiatry, School of Psychiatry and Neurosciences, University of Western Australia, Crawley, WA, Australia Department of Psychiatry, University of Cape Town, Cape Town, South Africa Cardiovascular Research Center, Faculty of Health Sciences, Australian Catholic University, Fitzroy, VIC, Australia
| |
Collapse
|
12
|
Mancuso SG, Newton JR, Bosanac P, Rossell SL, Nesci JB, Castle DJ. Classification of eating disorders: comparison of relative prevalence rates using DSM-IV and DSM-5 criteria. Br J Psychiatry 2015; 206:519-20. [PMID: 25745131 DOI: 10.1192/bjp.bp.113.143461] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2013] [Accepted: 09/26/2014] [Indexed: 11/23/2022]
Abstract
DSM-5 contains substantial changes to eating disorder diagnoses. We examined relative prevalence rates of DSM-IV and DSM-5 eating disorder diagnoses using Eating Disorder Examination-Questionnaire diagnostic algorithms in 117 community out-patients. DSM-5 criteria produced a reduction in combined 'other specified feeding or eating disorder' and 'unspecified feeding or eating disorder' from 46% to 29%, an increase in anorexia nervosa diagnoses from 35% to 47%, the same number of bulimia nervosa diagnoses and a 5% rate of binge eating disorder diagnoses.
Collapse
Affiliation(s)
- Serafino G Mancuso
- Serafino G. Mancuso, PhD, St Vincent's Mental Health, Melbourne, Department of Psychiatry, The University of Melbourne, Melbourne and Centre for Excellence in Research Methods, Eastern Hill Academic Centre, Department of Medicine, The University of Melbourne, Melbourne; J. Richard Newton, MBChB, MRCPsych, Department of Psychiatry, The University of Melbourne, Melbourne, Mental Health Clinical Service Unit, Austin Health, Melbourne and Department of Psychological Medicine, Monash University, Melbourne; Peter Bosanac, MD, FRANZCP, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne; Susan L. Rossell, PhD, Department of Psychiatry, The University of Melbourne, Melbourne and Psychological and Statistical Sciences, Faculty of Life and Social Sciences, Swinburne University of Technology, Melbourne; Julian B. Nesci, DPsych(Clin), St Vincent's Mental Health, Melbourne and Mental Health Clinical Service Unit, Austin Health, Melbourne, Australia; David J. Castle, MD, MRCPsych, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| | - J Richard Newton
- Serafino G. Mancuso, PhD, St Vincent's Mental Health, Melbourne, Department of Psychiatry, The University of Melbourne, Melbourne and Centre for Excellence in Research Methods, Eastern Hill Academic Centre, Department of Medicine, The University of Melbourne, Melbourne; J. Richard Newton, MBChB, MRCPsych, Department of Psychiatry, The University of Melbourne, Melbourne, Mental Health Clinical Service Unit, Austin Health, Melbourne and Department of Psychological Medicine, Monash University, Melbourne; Peter Bosanac, MD, FRANZCP, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne; Susan L. Rossell, PhD, Department of Psychiatry, The University of Melbourne, Melbourne and Psychological and Statistical Sciences, Faculty of Life and Social Sciences, Swinburne University of Technology, Melbourne; Julian B. Nesci, DPsych(Clin), St Vincent's Mental Health, Melbourne and Mental Health Clinical Service Unit, Austin Health, Melbourne, Australia; David J. Castle, MD, MRCPsych, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| | - Peter Bosanac
- Serafino G. Mancuso, PhD, St Vincent's Mental Health, Melbourne, Department of Psychiatry, The University of Melbourne, Melbourne and Centre for Excellence in Research Methods, Eastern Hill Academic Centre, Department of Medicine, The University of Melbourne, Melbourne; J. Richard Newton, MBChB, MRCPsych, Department of Psychiatry, The University of Melbourne, Melbourne, Mental Health Clinical Service Unit, Austin Health, Melbourne and Department of Psychological Medicine, Monash University, Melbourne; Peter Bosanac, MD, FRANZCP, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne; Susan L. Rossell, PhD, Department of Psychiatry, The University of Melbourne, Melbourne and Psychological and Statistical Sciences, Faculty of Life and Social Sciences, Swinburne University of Technology, Melbourne; Julian B. Nesci, DPsych(Clin), St Vincent's Mental Health, Melbourne and Mental Health Clinical Service Unit, Austin Health, Melbourne, Australia; David J. Castle, MD, MRCPsych, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| | - Susan L Rossell
- Serafino G. Mancuso, PhD, St Vincent's Mental Health, Melbourne, Department of Psychiatry, The University of Melbourne, Melbourne and Centre for Excellence in Research Methods, Eastern Hill Academic Centre, Department of Medicine, The University of Melbourne, Melbourne; J. Richard Newton, MBChB, MRCPsych, Department of Psychiatry, The University of Melbourne, Melbourne, Mental Health Clinical Service Unit, Austin Health, Melbourne and Department of Psychological Medicine, Monash University, Melbourne; Peter Bosanac, MD, FRANZCP, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne; Susan L. Rossell, PhD, Department of Psychiatry, The University of Melbourne, Melbourne and Psychological and Statistical Sciences, Faculty of Life and Social Sciences, Swinburne University of Technology, Melbourne; Julian B. Nesci, DPsych(Clin), St Vincent's Mental Health, Melbourne and Mental Health Clinical Service Unit, Austin Health, Melbourne, Australia; David J. Castle, MD, MRCPsych, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| | - Julian B Nesci
- Serafino G. Mancuso, PhD, St Vincent's Mental Health, Melbourne, Department of Psychiatry, The University of Melbourne, Melbourne and Centre for Excellence in Research Methods, Eastern Hill Academic Centre, Department of Medicine, The University of Melbourne, Melbourne; J. Richard Newton, MBChB, MRCPsych, Department of Psychiatry, The University of Melbourne, Melbourne, Mental Health Clinical Service Unit, Austin Health, Melbourne and Department of Psychological Medicine, Monash University, Melbourne; Peter Bosanac, MD, FRANZCP, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne; Susan L. Rossell, PhD, Department of Psychiatry, The University of Melbourne, Melbourne and Psychological and Statistical Sciences, Faculty of Life and Social Sciences, Swinburne University of Technology, Melbourne; Julian B. Nesci, DPsych(Clin), St Vincent's Mental Health, Melbourne and Mental Health Clinical Service Unit, Austin Health, Melbourne, Australia; David J. Castle, MD, MRCPsych, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| | - David J Castle
- Serafino G. Mancuso, PhD, St Vincent's Mental Health, Melbourne, Department of Psychiatry, The University of Melbourne, Melbourne and Centre for Excellence in Research Methods, Eastern Hill Academic Centre, Department of Medicine, The University of Melbourne, Melbourne; J. Richard Newton, MBChB, MRCPsych, Department of Psychiatry, The University of Melbourne, Melbourne, Mental Health Clinical Service Unit, Austin Health, Melbourne and Department of Psychological Medicine, Monash University, Melbourne; Peter Bosanac, MD, FRANZCP, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne; Susan L. Rossell, PhD, Department of Psychiatry, The University of Melbourne, Melbourne and Psychological and Statistical Sciences, Faculty of Life and Social Sciences, Swinburne University of Technology, Melbourne; Julian B. Nesci, DPsych(Clin), St Vincent's Mental Health, Melbourne and Mental Health Clinical Service Unit, Austin Health, Melbourne, Australia; David J. Castle, MD, MRCPsych, St Vincent's Mental Health, Melbourne and Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| |
Collapse
|
13
|
Mancuso SG, Morgan VA, Mitchell PB, Berk M, Young A, Castle DJ. A comparison of schizophrenia, schizoaffective disorder, and bipolar disorder: Results from the Second Australian national psychosis survey. J Affect Disord 2015; 172:30-7. [PMID: 25451392 DOI: 10.1016/j.jad.2014.09.035] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Revised: 09/18/2014] [Accepted: 09/21/2014] [Indexed: 10/24/2022]
Abstract
INTRODUCTION It remains uncertain whether schizoaffective disorder (SAD) is a discrete diagnostic entity, is a variant of either a psychotic mood disorder such as bipolar disorder (BDP) or schizophrenia (SCZ), or exists on a spectral continuum between these disorders. The present study examined whether SCZ, SAD, and BDP differed qualitatively on demographic and clinical variables based on a large Australian dataset. METHODS This study examined data from the Australian Survey of High Impact Psychosis (SHIP), in which 1469 of the 1825 participants in who had an ICD-10 diagnosis of SCZ (n=857), SAD (n=293), and BDP (n=319) were assessed across a broad range of variables. RESULTS When compared to patients with SCZ, those with SAD reported more current delusional and thought disorder symptoms, a greater number of lifetime depression, mania, and positive symptoms, and fewer negative symptoms. Relative to the BPD group, the SAD group were younger, endorsed more current positive, delusional, and thought disorder symptoms, fewer lifetime mania symptoms, more lifetime psychotic, hallucination, and delusional symptoms, and recorded lower premorbid IQ scores. Compared to patients with BPD, those with SCZ were significantly younger, endorsed more current psychotic and hallucination symptoms, fewer lifetime depression and mania symptoms, more lifetime psychotic, hallucination, and delusional symptoms, reported more negative symptoms and had lower premorbid IQ and psychosocial functioning scores. LIMITATIONS Validated psychometric measures of psychotic or mood symptoms were not used. CONCLUSION This pattern of results is consistent with the conceptualisation of a spectrum of disorders, ranging from BDP at one end, to SAD in the middle, and SCZ at the other end.
Collapse
Affiliation(s)
- Serafino G Mancuso
- St Vincent׳s Mental Health, Fitzroy, VIC, Australia; Department of Psychiatry, the University of Melbourne, Parkville, VIC, Australia.
| | - Vera A Morgan
- Neuropsychiatric Epidemiology Research Unit, School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Crawley, WA, Australia
| | - Philip B Mitchell
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia; Black Dog Institute, Sydney, NSW, Australia
| | - Michael Berk
- St Vincent׳s Mental Health, Fitzroy, VIC, Australia; IMPACT Strategic Research Centre, Deakin University, School of Medicine, Barwon Health, Geelong, VIC, Australia; Orygen Youth Health Research Centre, Parkville, VIC, Australia; Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia
| | - Allan Young
- Centre for Affective Disorders, Institute of Psychiatry, King׳s College London, London, United Kingdom
| | - David J Castle
- St Vincent׳s Mental Health, Fitzroy, VIC, Australia; Department of Psychiatry, the University of Melbourne, Parkville, VIC, Australia
| |
Collapse
|
14
|
Moore E, Mancuso SG, Slade T, Galletly C, Castle DJ. The impact of alcohol and illicit drugs on people with psychosis: the second Australian National Survey of Psychosis. Aust N Z J Psychiatry 2012; 46:864-78. [PMID: 22472772 DOI: 10.1177/0004867412443900] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To provide the most up-to-date prevalence estimates of alcohol and illicit drug use among individuals with psychosis in Australia, and explore correlates associated with a lifetime diagnosis of both alcohol abuse/dependence and cannabis abuse/dependence. METHOD This paper uses data from the Survey of High Impact Psychosis (SHIP), conducted as a follow-up to the first Australian National Low Prevalence (Psychotic) Disorders Study (1997-1998). The SHIP was a national study, carried out across five states, in which a sample of 1825 individuals was recruited through a two-phase sampling framework. RESULTS Alcohol and illicit drug use was highly prevalent for the entire sample. There were few significant differences in the prevalence or frequency of use across the diagnostic categories examined. Substantial increases in substance abuse/dependence were noted since the 1997-1998 survey (51% diagnosed with alcohol abuse/dependence, 51% with cannabis abuse/dependence and 32% with other illicit drug abuse/dependence, compared to 28%, 23% and 12% respectively, in the 1997-1998 survey by Kavanagh et al., 2004). Factors significantly associated with both lifetime alcohol and cannabis dependence included male gender, younger age, single marital status, lower educational attainment, shorter duration of illness, lifetime presence of hallucinations, higher negative syndrome score and lower body mass index (BMI). A number of other factors were found to be differentially associated with either lifetime alcohol or cannabis dependence. CONCLUSIONS The use of alcohol and illicit substances is common among people with a psychotic illness, with a concerning upward trend in rates of substance abuse/dependence since the 1997-1998 survey. Clinicians should be aware of the potential impact of concurrent substance use and provide integrated treatment for individuals presenting with psychotic illnesses. More research and investment in new intervention programs is required.
Collapse
Affiliation(s)
- Elizabeth Moore
- School of Psychiatry, University of New South Wales, Sydney, Australia
| | | | | | | | | |
Collapse
|
15
|
Cooper J, Mancuso SG, Borland R, Slade T, Galletly C, Castle D. Tobacco smoking among people living with a psychotic illness: the second Australian Survey of Psychosis. Aust N Z J Psychiatry 2012; 46:851-63. [PMID: 22645396 DOI: 10.1177/0004867412449876] [Citation(s) in RCA: 123] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVE The aims of this study were to (a) describe patterns of tobacco smoking among Australians living with a psychotic illness and (b) explore the association between smoking and measures of psychopathology, psychiatric history, psychosocial functioning, physical health, substance use and demographic characteristics. METHODS Data were from 1812 participants in the 2010 Australian Survey of High Impact Psychosis. Participants were aged 18-64 years and resided in seven mental health catchment sites across five states of Australia. Bivariate statistics were used to compare smokers with non-smokers on the measures of interest, and to compare ICD-10 diagnostic categories on measures of smoking prevalence, nicotine addiction and quitting history. Multivariate logistic regression was used to test whether (a) demographics and psychiatric history were associated with having ever smoked and (b) whether symptoms and psychosocial functioning were independently associated with current smoking, after controlling for demographics, psychiatric history and substance use. RESULTS The prevalence of current tobacco smoking was 66.6% (72% of men and 59% of women); lifetime prevalence was 81%. In univariate analyses, individuals with a diagnosis of schizophrenia or schizoaffective disorder were most likely to be smoking tobacco (70%) and were more nicotine dependent. Smokers reported worse perceived physical health, lower body mass index and waist circumference, and more lifetime medical conditions. A younger age of illness onset, male gender and low education were associated with having ever smoked. Associations with current smoking included low education, male gender, no formal employment, worse negative symptoms, higher daily caffeine consumption, and alcohol dependence and substance abuse/dependence. CONCLUSIONS The prevalence of tobacco smoking is high amongst people with a psychotic disorder, and is associated with adverse mental health symptoms as well as high rates of other substance use, poorer subjective physical health, and a higher risk of the many known health consequences of smoking.
Collapse
Affiliation(s)
- Jae Cooper
- VicHealth Centre for Tobacco Control, Cancer Council Victoria, Carlton, Australia
| | | | | | | | | | | |
Collapse
|